What is Sorrento Therapeutics Inc's earnings per share (EPS)?

Sorrento Therapeutics Inc (SRNE) reported diluted earnings per share of $-1.37 for fiscal year 2022. This represents a 5.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sorrento Therapeutics Inc Financials

SRNE

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2023 Currency USD FYE December

This page shows Sorrento Therapeutics Inc (SRNE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SRNE FY2022 2026-04-22

External financing kept a development-stage cash burn running, but FY2022 shows the balance sheet absorbing less shock.

In FY2022, financing inflows of $311.7M almost matched free-cash burn of $307.5M, yet cash still ended at only $23.6M and equity turned negative. Compared with FY2021, that means fresh capital was largely replacing consumed capital rather than rebuilding liquidity, so the funding mechanism was working harder while the cushion got thinner despite the large raise.

R&D intensity remained far larger than the current sales base: FY2022 research spending was $221.2M against revenue of $62.8M. Revenue expanded over FY2020-FY2022, but operating losses widened and cash burn stayed heavy, so added scale was not yet absorbing the fixed cost base.

Balance-sheet pressure became more immediate even though long-term debt fell to $19.1M. Current liabilities climbed to $327.9M and the current ratio sank to 0.3x, while shares outstanding rose to 522.8M from 314.6M in one year, showing reliance shifted toward equity issuance and short-dated obligations rather than internally generated cash, leaving less room to self-fund surprises.

Financial Health Signals

Financial health score pending refresh

We are recalculating Sorrento Therapeutics Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Distress

-9.77

Sorrento Therapeutics Inc scores -9.77, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.9M) relative to total liabilities ($494.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Sorrento Therapeutics Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.51x

For every $1 of reported earnings, Sorrento Therapeutics Inc generates $0.51 in operating cash flow (-$293.9M OCF vs -$572.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-58.8x

Sorrento Therapeutics Inc earns $-58.8 in operating income for every $1 of interest expense (-$504.3M vs $8.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$62.8M

YoY+18.8%

5Y CAGR-16.2%

10Y CAGR+59.7%

Sorrento Therapeutics Inc generated $62.8M in revenue in fiscal year 2022. This represents an increase of 18.8% from the prior year.

EBITDA

-$491.1M

YoY-26.2%

Sorrento Therapeutics Inc's EBITDA was -$491.1M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 26.2% from the prior year.

Net Income

-$572.8M

YoY-33.7%

Sorrento Therapeutics Inc reported -$572.8M in net income in fiscal year 2022. This represents a decrease of 33.7% from the prior year.

EPS (Diluted)

$-1.37

YoY+5.5%

Sorrento Therapeutics Inc earned $-1.37 per diluted share (EPS) in fiscal year 2022. This represents an increase of 5.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$307.5M

YoY-5.8%

Sorrento Therapeutics Inc generated -$307.5M in free cash flow in fiscal year 2022, representing cash available after capex. This represents a decrease of 5.8% from the prior year.

Cash & Debt

$23.6M

YoY-35.5%

5Y CAGR+3.0%

10Y CAGR+16.6%

Sorrento Therapeutics Inc held $23.6M in cash against $19.1M in long-term debt as of fiscal year 2022.

Dividends Per Share

N/A

Shares Outstanding

523M

YoY+66.2%

5Y CAGR+44.5%

10Y CAGR+45.8%

Sorrento Therapeutics Inc had 523M shares outstanding in fiscal year 2022. This represents an increase of 66.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-802.5%

YoY-43.7pp

5Y CAGR-819.2pp

10Y CAGR+28.3pp

Sorrento Therapeutics Inc's operating margin was -802.5% in fiscal year 2022, reflecting core business profitability. This is down 43.7 percentage points from the prior year.

Net Margin

-911.6%

YoY-102.0pp

5Y CAGR-917.6pp

10Y CAGR-82.0pp

Sorrento Therapeutics Inc's net profit margin was -911.6% in fiscal year 2022, showing the share of revenue converted to profit. This is down 102.0 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$221.2M

YoY+6.9%

5Y CAGR+53.3%

10Y CAGR+50.0%

Sorrento Therapeutics Inc invested $221.2M in research and development in fiscal year 2022. This represents an increase of 6.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$13.7M

YoY+54.0%

5Y CAGR+4.5%

10Y CAGR+37.9%

Sorrento Therapeutics Inc invested $13.7M in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents an increase of 54.0% from the prior year.

SRNE Income Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Revenue	$62.8M+18.8%	$52.9M+32.3%	$40.0M+27.2%	$31.4M+48.3%	$21.2M-86.0%	$151.9M
Cost of Revenue	N/A	N/A	N/A	N/A	$7.1M+79.0%	$3.9M
Gross Profit	N/A	N/A	N/A	N/A	$14.1M-90.4%	$147.9M
R&D Expenses	$221.2M+6.9%	$206.9M+85.8%	$111.3M+4.2%	$106.9M+845.5%	$11.3M-56.7%	$26.1M
SG&A Expenses	$182.3M-7.4%	$196.9M+69.4%	$116.2M+12.2%	$103.6M+62.7%	$63.6M+66.0%	$38.3M
Operating Income	-$504.3M-25.6%	-$401.5M-64.2%	-$244.5M+5.7%	-$259.4M-72.4%	-$150.4M-693.7%	$25.3M
Interest Expense	$8.6M-16.1%	$10.2M-49.3%	$20.2M-42.5%	$35.0M-39.2%	$57.6M+1057.2%	$5.0M
Income Tax	-$2.4M+92.8%	-$33.5M-1564.2%	-$2.0M-325.8%	-$473K+92.5%	-$6.3M+82.6%	-$36.0M
Net Income	-$572.8M-33.7%	-$428.3M-43.5%	-$298.5M-2.2%	-$292.1M-43.5%	-$203.5M-2328.9%	$9.1M
EPS (Diluted)	$-1.37+5.5%	$-1.45-11.5%	$-1.30+44.7%	$-2.35-22.4%	$-1.92-1576.9%	$0.13

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Revenue	$15.0M-7.5%	$16.3M+4.2%	$15.6M-10.4%	$17.4M+51.8%	$11.5M-37.7%	$18.4M+40.6%	$13.1M+8.4%	$12.1M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$33.3M-24.0%	$43.8M+7.4%	$40.8M-40.0%	$68.0M+40.3%	$48.5M-24.2%	$64.0M	N/A	$49.4M
SG&A Expenses	$48.9M-11.0%	$55.0M+38.4%	$39.7M-20.8%	$50.2M+4.2%	$48.1M+8.6%	$44.3M	N/A	$48.5M
Operating Income	-$77.2M+27.4%	-$106.3M+37.3%	-$169.6M-55.0%	-$109.4M+7.5%	-$118.4M-10.7%	-$106.9M	N/A	-$101.4M
Interest Expense	$2.7M+135.7%	$1.1M-49.0%	$2.2M+180.2%	$792K-65.8%	$2.3M-28.8%	$3.2M	N/A	$2.9M
Income Tax	$671K-94.1%	$11.5M+732.2%	-$1.8M-78.7%	-$1.0M+3.3%	-$1.1M-171.8%	$1.5M	N/A	$386K
Net Income	-$95.2M+31.8%	-$139.6M+37.6%	-$223.7M-149.7%	-$89.6M+59.1%	-$218.8M-436.0%	-$40.8M+71.7%	-$144.4M-20.5%	-$119.8M
EPS (Diluted)	$-0.17+34.6%	$-0.26	N/A	$-0.20+63.0%	$-0.54-350.0%	$-0.12+74.5%	$-0.47-17.5%	$-0.40

SRNE Balance Sheet

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Total Assets	$472.8M-31.9%	$694.8M+29.7%	$535.8M-3.9%	$557.6M-10.6%	$624.1M+44.6%	$431.6M
Current Assets	$96.4M-44.3%	$173.0M+100.6%	$86.2M+27.6%	$67.6M-62.4%	$179.6M+504.6%	$29.7M
Cash & Equivalents	$23.6M-35.5%	$36.7M-35.1%	$56.5M+150.7%	$22.5M-85.8%	$158.7M+677.0%	$20.4M
Inventory	$10.0M+23.1%	$8.1M+342.7%	$1.8M-45.5%	$3.4M+16.0%	$2.9M	N/A
Accounts Receivable	$24.5M+30.7%	$18.7M+20.7%	$15.5M+7.3%	$14.5M+277.1%	$3.8M	N/A
Goodwill	$80.3M+0.9%	$79.5M+82.6%	$43.6M+13.7%	$38.3M0.0%	$38.3M0.0%	$38.3M
Total Liabilities	$494.5M-19.8%	$616.7M+56.1%	$395.1M-24.7%	$524.9M+26.0%	$416.6M+85.1%	$225.0M
Current Liabilities	$327.9M+135.1%	$139.5M+44.5%	$96.5M-16.3%	$115.2M+87.0%	$61.6M-22.0%	$79.0M
Long-Term Debt	$19.1M-82.7%	$110.6M+19.9%	$92.3M-53.7%	$199.1M-10.8%	$223.1M+4182.0%	$5.2M
Total Equity	-$18.6M-123.6%	$78.7M-52.3%	$165.2M+110.1%	$78.6M-62.5%	$209.5M+5.0%	$199.6M
Retained Earnings	-$2.0B-41.3%	-$1.4B-44.7%	-$958.3M-45.2%	-$659.8M-79.4%	-$367.8M-122.7%	-$165.1M

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Total Assets	$456.7M-0.7%	$460.1M-2.7%	$472.8M-23.2%	$615.6M-2.6%	$632.1M-26.1%	$855.6M+23.1%	$694.8M-7.7%	$752.8M
Current Assets	$133.1M+32.1%	$100.8M+4.6%	$96.4M-45.5%	$177.0M-9.7%	$196.0M-40.8%	$331.1M+91.4%	$173.0M-13.8%	$200.7M
Cash & Equivalents	$69.7M+85.2%	$37.7M+59.3%	$23.6M-66.6%	$70.7M+0.5%	$70.3M-37.1%	$111.9M+205.2%	$36.7M-7.7%	$39.7M
Inventory	$9.7M-14.7%	$11.3M+13.4%	$10.0M-44.5%	$18.0M-13.2%	$20.7M+46.9%	$14.1M+73.8%	$8.1M+49.4%	$5.4M
Accounts Receivable	$32.7M+23.4%	$26.5M+8.4%	$24.5M+1.2%	$24.2M-2.1%	$24.7M+0.2%	$24.7M+31.8%	$18.7M+13.7%	$16.5M
Goodwill	$80.3M0.0%	$80.3M0.0%	$80.3M+0.1%	$80.2M-1.4%	$81.4M+2.3%	$79.5M0.0%	$79.5M+50.4%	$52.9M
Total Liabilities	$654.6M+11.4%	$587.5M+18.8%	$494.5M+1.9%	$485.4M-2.2%	$496.4M-21.1%	$629.4M+2.1%	$616.7M-0.8%	$621.5M
Current Liabilities	$264.9M+60.0%	$165.6M-49.5%	$327.9M+62.4%	$202.0M+39.0%	$145.3M-28.8%	$204.2M+46.5%	$139.5M-20.4%	$175.2M
Long-Term Debt	$21.7M+1.6%	$21.4M+11.9%	$19.1M+7.5%	$17.8M-78.6%	$83.1M-13.5%	$96.1M-13.1%	$110.6M+32.5%	$83.5M
Total Equity	-$205.1M-63.4%	-$125.5M-574.5%	-$18.6M-114.1%	$131.8M-0.1%	$132.0M-41.7%	$226.5M+187.7%	$78.7M-40.1%	$131.5M
Retained Earnings	-$2.2B-4.5%	-$2.1B-7.1%	-$2.0B-12.9%	-$1.7B-5.4%	-$1.6B-15.3%	-$1.4B-2.9%	-$1.4B-11.6%	-$1.2B

SRNE Cash Flow Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Operating Cash Flow	-$293.9M-4.3%	-$281.8M-76.7%	-$159.5M+7.8%	-$173.0M-54.8%	-$111.8M-12.7%	-$99.2M
Capital Expenditures	$13.7M+54.0%	$8.9M+35.9%	$6.5M-42.9%	$11.4M+2.2%	$11.2M+2.0%	$11.0M
Free Cash Flow	-$307.5M-5.8%	-$290.7M-75.0%	-$166.1M+10.0%	-$184.4M-50.0%	-$123.0M-11.6%	-$110.2M
Investing Cash Flow	-$28.5M-135.7%	$79.8M+300.0%	-$39.9M-4.6%	-$38.2M-80.1%	-$21.2M-28.2%	-$16.5M
Financing Cash Flow	$311.7M+71.9%	$181.3M+4.1%	$174.2M+120.9%	$78.9M-75.8%	$326.0M+507.4%	$53.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$0	$0

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Operating Cash Flow	-$55.7M-12.5%	-$49.5M+27.6%	-$68.3M-11.7%	-$61.2M+24.5%	-$81.0M+2.8%	-$83.4M-15.6%	-$72.1M+13.2%	-$83.1M
Capital Expenditures	$140K+62.8%	$86K-98.1%	$4.5M+18.0%	$3.8M+41.8%	$2.7M+4.3%	$2.6M+17.4%	$2.2M+88.0%	$1.2M
Free Cash Flow	-$55.8M-12.6%	-$49.5M+32.0%	-$72.9M-12.1%	-$65.0M+22.3%	-$83.7M+2.6%	-$86.0M-15.6%	-$74.3M+11.8%	-$84.3M
Investing Cash Flow	-$140K-108.3%	$1.7M+133.5%	-$5.0M+37.8%	-$8.1M-368.3%	-$1.7M+87.4%	-$13.7M-519.7%	-$2.2M-140.9%	$5.4M
Financing Cash Flow	$88.8M+45.1%	$61.2M+144.0%	$25.1M-64.9%	$71.5M+71.2%	$41.8M-75.9%	$173.4M+144.7%	$70.9M+76.9%	$40.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SRNE Financial Ratios

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Gross Margin	N/A	N/A	N/A	N/A	66.7%-30.7pp	97.4%
Operating Margin	-802.5%-43.7pp	-758.8%-147.3pp	-611.5%+213.7pp	-825.3%-115.5pp	-709.8%-726.5pp	16.7%
Net Margin	-911.6%-102.0pp	-809.6%-63.2pp	-746.4%+182.8pp	-929.2%+31.2pp	-960.4%-966.4pp	6.0%
Return on Equity	N/A	-543.9%-363.2pp	-180.7%+190.9pp	-371.6%-274.5pp	-97.2%-101.8pp	4.6%
Return on Assets	-121.2%-59.5pp	-61.7%-5.9pp	-55.7%-3.3pp	-52.4%-19.8pp	-32.6%-34.7pp	2.1%
Current Ratio	0.29-0.9	1.24+0.3	0.89+0.3	0.59-2.3	2.91+2.5	0.38
Debt-to-Equity	N/A	1.40+0.8	0.56-2.0	2.53+1.5	1.07+1.0	0.03
FCF Margin	-489.4%+60.1pp	-549.5%-134.2pp	-415.3%+171.5pp	-586.8%-6.6pp	-580.2%-507.7pp	-72.5%

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-514.0%+140.4pp	-654.4%+433.5pp	-1087.9%-458.9pp	-629.0%+403.7pp	-1032.7%-451.4pp	-581.4%	N/A	-840.5%
Net Margin	-633.7%+225.4pp	-859.1%+575.5pp	-1434.6%-919.8pp	-514.8%+1393.9pp	-1908.7%-1686.7pp	-222.0%+882.4pp	-1104.4%-111.2pp	-993.2%
Return on Equity	N/A	N/A	N/A	-67.9%+97.8pp	-165.7%-147.7pp	-18.0%+165.4pp	-183.4%-92.3pp	-91.1%
Return on Assets	-20.8%+9.5pp	-30.3%+17.0pp	-47.3%-32.8pp	-14.5%+20.1pp	-34.6%-29.8pp	-4.8%+16.0pp	-20.8%-4.9pp	-15.9%
Current Ratio	0.50-0.1	0.61+0.3	0.29-0.6	0.88-0.5	1.35-0.3	1.62+0.4	1.24+0.1	1.15
Debt-to-Equity	N/A	N/A	N/A	0.14-0.5	0.63+0.2	0.42-1.0	1.40+0.8	0.63
FCF Margin	-371.4%-66.5pp	-304.9%+162.4pp	-467.3%-93.7pp	-373.6%+356.6pp	-730.2%-262.7pp	-467.5%+101.0pp	-568.6%+130.2pp	-698.8%

Note: Shareholder equity is negative (-$18.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.29), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Aim Immunotech AIMI

$2.0M

Enzolytics ENZC

$1.9M

Neon Bloom NBCO

$1.3M

GREY MATTERS HEALTH INC, AGNPF

$1.7M

Axim Biotechnologies Inc AXIM

$1.7M

Frequently Asked Questions

What is Sorrento Therapeutics Inc's annual revenue?

Sorrento Therapeutics Inc (SRNE) reported $62.8M in total revenue for fiscal year 2022. This represents a 18.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Sorrento Therapeutics Inc's revenue growing?

Sorrento Therapeutics Inc (SRNE) revenue grew by 18.8% year-over-year, from $52.9M to $62.8M in fiscal year 2022.

Is Sorrento Therapeutics Inc profitable?

No, Sorrento Therapeutics Inc (SRNE) reported a net income of -$572.8M in fiscal year 2022, with a net profit margin of -911.6%.

What is Sorrento Therapeutics Inc's EBITDA?

Sorrento Therapeutics Inc (SRNE) had EBITDA of -$491.1M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Sorrento Therapeutics Inc have?

As of fiscal year 2022, Sorrento Therapeutics Inc (SRNE) had $23.6M in cash and equivalents against $19.1M in long-term debt.

What is Sorrento Therapeutics Inc's operating margin?

Sorrento Therapeutics Inc (SRNE) had an operating margin of -802.5% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.

What is Sorrento Therapeutics Inc's net profit margin?

Sorrento Therapeutics Inc (SRNE) had a net profit margin of -911.6% in fiscal year 2022, representing the share of revenue converted into profit after all expenses.

What is Sorrento Therapeutics Inc's free cash flow?

Sorrento Therapeutics Inc (SRNE) generated -$307.5M in free cash flow during fiscal year 2022. This represents a -5.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Sorrento Therapeutics Inc's operating cash flow?

Sorrento Therapeutics Inc (SRNE) generated -$293.9M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.

What are Sorrento Therapeutics Inc's total assets?

Sorrento Therapeutics Inc (SRNE) had $472.8M in total assets as of fiscal year 2022, including both current and long-term assets.

What are Sorrento Therapeutics Inc's capital expenditures?

Sorrento Therapeutics Inc (SRNE) invested $13.7M in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.

How much does Sorrento Therapeutics Inc spend on research and development?

Sorrento Therapeutics Inc (SRNE) invested $221.2M in research and development during fiscal year 2022.

How many shares does Sorrento Therapeutics Inc have outstanding?

Sorrento Therapeutics Inc (SRNE) had 523M shares outstanding as of fiscal year 2022.

What is Sorrento Therapeutics Inc's current ratio?

Sorrento Therapeutics Inc (SRNE) had a current ratio of 0.29 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.

What is Sorrento Therapeutics Inc's return on assets (ROA)?

Sorrento Therapeutics Inc (SRNE) had a return on assets of -121.2% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.

What is Sorrento Therapeutics Inc's cash runway?

Based on fiscal year 2022 data, Sorrento Therapeutics Inc (SRNE) had $23.6M in cash against an annual operating cash burn of $293.9M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Sorrento Therapeutics Inc's debt-to-equity ratio negative or not reported?

Sorrento Therapeutics Inc (SRNE) has negative shareholder equity of -$18.6M as of fiscal year 2022, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Sorrento Therapeutics Inc's Altman Z-Score?

Sorrento Therapeutics Inc (SRNE) has an Altman Z-Score of -9.77, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Sorrento Therapeutics Inc's Piotroski F-Score?

Sorrento Therapeutics Inc (SRNE) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sorrento Therapeutics Inc's earnings high quality?

Sorrento Therapeutics Inc (SRNE) has an earnings quality ratio of 0.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Sorrento Therapeutics Inc cover its interest payments?

Sorrento Therapeutics Inc (SRNE) has an interest coverage ratio of -58.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.